| | | | | The U.S. Food and Drug Administration said on Monday it approved a drug from Global Blood Therapeutics Inc to treat sickle cell disease in adults and children 12 years or older. | | |
| | | (Reuters Health) - Mentally ill homeless adults may have an easier time finding and keeping stable housing when they receive rent supplements and mental health support services, a Canadian study suggests. | | |
| | | (Reuters Health) - Teens and young adults who use cocaine, amphetamines and cannabis are more likely to be hospitalized for heart attacks by early adulthood than their counterparts who don't use these drugs, a recent study suggests. | | |
| | | (Reuters Health) - One in eight adults with heart disease delays filling prescriptions. takes less of the medication than prescribed, or skips medications altogether because of high out-of-pocket costs, a new study suggests. | | |
| | | Roche's influenza treatment Xofluza, a one-dose pill that can clear flu symptoms within days, may cause a mutation of the virus that leads to drug resistance, researchers reported on Monday. | | |
| | | CymaBay Therapeutics Inc said on Monday it was scrapping two mid-stage trials of its liver disease drug, after biopsies found a type of liver damage in some patients, sending its shares down over 75%. | | |
| | | Adamis Pharmaceuticals Corp said on Monday the U.S. Food and Drug Administration declined to approve its opioid overdose treatment, Zimhi, sending its shares plunging 56%. | | |
| | | Teva Pharmaceutical Industries on Monday signed research agreements with two leading Israeli academic institutes, a move to boost its early-stage drug development with a focus on cancer treatments. | | |
| | | Blackstone Group Inc said on Monday it will invest $400 million in a joint venture with Swiss drug company Ferring that is working on an experimental gene therapy for bladder cancer, the private equity giant's largest ever bet on drug development. | | |
| | | Roche expects its risdiplam medicine for spinal muscular atrophy (SMA) to get U.S. approval by May, the Swiss drugmaker said on Monday, as it takes on Novartis and Biogen in the lucrative rare disease area. | | |
| | | (This Nov. 23rd story corrects fiscal year of expected regulatory approval in the 10th paragraph to March-end 2021, not March-end 2020) | | |
|
| |
